Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ONCY accumulated deficit (Tax losses applied to a buyout)

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Feb 21, 2024 6:33pm

152 Views

Post# 35892095

RE:ONCY accumulated deficit (Tax losses applied to a buyout)

ONCY raised approximately $450 million over its lifetime and not $3/4 Billion as one has tried to pass-off. This $450 million is reported in ONCY's financial statements as the "accumulated deficit".

The accumulated deficit represents a basic underlying value of at least US$ 4.25 per share ..... which is one of the reasons why analysts covering ONCY have a near term target value of at least $5+ per share.

<< Previous

Bullboard Posts

Next >>

How to navigate the ups and downs of investing in AI